Skip to main content

Table 2 Assessing risk of bias of the included studies by validated Jadad 5-point scale

From: Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Author

Publication year

Country

Sample size (n)

Study Design

Randomization (0–2 points)

Double-blind (0–2 points)

Drop-outs and withdrawals (0–1 points)

Jadad score

Sprague [27]

2003

USA

263

multicenter, double-blind, parallel

1

2

1

4

Gafor [26]

2009

Malaysia

25

single-center, open-labelled, parallel

1

0

1

2

Lund [25]

2010

USA

18

single-center, double-blind, crossover

1

2

1

4

Hansen [24]

2011

Denmark

86

multicenter, open-labelled, crossover

2

0

1

3

Ong [23]

2013

Malaysia

66

multicentre, open-labelled, parallel

1

0

1

2

Jamaluddin [22]

2014

Malaysia

26

single-center, open-labelled, parallel

1

0

1

2

Akizawa [21]

2015

Japan

255

multicenter, double-blind, parallel

1

2

1

4

Veceric [28]

2016

Slovenia

20

single-center, open-labelled, parallel

1

0

0

1